CY1113083T1 - Ασβεστιολυτικες ενωσεις - Google Patents

Ασβεστιολυτικες ενωσεις

Info

Publication number
CY1113083T1
CY1113083T1 CY20121100784T CY121100784T CY1113083T1 CY 1113083 T1 CY1113083 T1 CY 1113083T1 CY 20121100784 T CY20121100784 T CY 20121100784T CY 121100784 T CY121100784 T CY 121100784T CY 1113083 T1 CY1113083 T1 CY 1113083T1
Authority
CY
Cyprus
Prior art keywords
calcium compounds
compounds
calcium
calculolytic
novel
Prior art date
Application number
CY20121100784T
Other languages
English (en)
Inventor
Robert W Marquis
Linda N Casillas
Joshi M Ramanjulu
James Francis Callahan
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1113083T1 publication Critical patent/CY1113083T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Παρέχονται καινοφανείς ασβεστιολυτικές ενώσεις και μέθοδοι χρήσης αυτών.
CY20121100784T 2002-11-26 2012-09-03 Ασβεστιολυτικες ενωσεις CY1113083T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26
EP03783752A EP1569892B1 (en) 2002-11-26 2003-11-25 Calcilytic compounds

Publications (1)

Publication Number Publication Date
CY1113083T1 true CY1113083T1 (el) 2016-04-13

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100784T CY1113083T1 (el) 2002-11-26 2012-09-03 Ασβεστιολυτικες ενωσεις

Country Status (33)

Country Link
US (6) US7514473B2 (el)
EP (1) EP1569892B1 (el)
JP (1) JP4489597B2 (el)
KR (2) KR20050086786A (el)
CN (1) CN1325466C (el)
AP (1) AP2113A (el)
AR (1) AR042132A1 (el)
AU (1) AU2003291157C1 (el)
BR (1) BR0316544A (el)
CA (1) CA2507226C (el)
CO (1) CO5570664A2 (el)
CY (1) CY1113083T1 (el)
DK (1) DK1569892T3 (el)
EA (1) EA009603B1 (el)
ES (1) ES2388277T3 (el)
HK (1) HK1082914A1 (el)
IL (1) IL168704A (el)
IS (1) IS2897B (el)
MA (1) MA27528A1 (el)
MX (1) MXPA05005574A (el)
MY (1) MY143244A (el)
NO (1) NO332304B1 (el)
NZ (1) NZ540275A (el)
OA (1) OA12962A (el)
PE (1) PE20040845A1 (el)
PL (1) PL211571B1 (el)
PT (1) PT1569892E (el)
SI (1) SI1569892T1 (el)
TW (1) TWI316511B (el)
UA (1) UA81642C2 (el)
UY (1) UY28089A1 (el)
WO (1) WO2004047751A2 (el)
ZA (1) ZA200504104B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
WO2005077886A1 (en) * 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
TW200845956A (en) * 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
JP5025795B2 (ja) * 2008-06-05 2012-09-12 旭化成ファーマ株式会社 スルホンアミド化合物及びその用途
CN102307847A (zh) 2008-12-24 2012-01-04 第一三共株式会社 茚满基化合物
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (en) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (el)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (el) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
EA002984B1 (ru) 1996-04-09 2002-12-26 Эн Пи Эс Фармасьютикалз, Инк. Кальцилитические соединения, фармацевтические композиции и способ скрининга кальцилитических соединений
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
US20020019440A1 (en) 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
JP2001519813A (ja) 1997-04-04 2001-10-23 スミスクライン・ビーチャム・コーポレイション カルシウム溶解性化合物
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
DE19913753A1 (de) 1998-04-01 1999-10-07 Mannesmann Rexroth Ag Verfahren zur Bildung des Mittelwertes
MY121054A (en) 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
US6291459B1 (en) 1998-08-12 2001-09-18 Smithkline Beecham Corporation Calcilytic compounds
WO2000009491A1 (en) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
AR030684A1 (es) 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
CZ2003142A3 (cs) 2000-07-21 2003-06-18 Smithkline Beecham Corporation Kalcilytické sloučeniny
EP1383511B1 (en) 2000-10-25 2006-10-25 SmithKline Beecham Corporation Calcilytic compounds
CZ20031144A3 (cs) 2000-10-25 2004-08-18 Smithklineábeechamácorporation Kalcilytické sloučeniny
WO2002072760A2 (en) 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pcra helicase inhibitors
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
TWI316511B (en) * 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
ATE489368T1 (de) 2003-04-07 2010-12-15 Nps Pharma Inc Pyrimidinonverbindungen als calcilytica
WO2005018561A2 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
TW200524892A (en) 2003-09-24 2005-08-01 Glaxo Group Ltd Calcilytic compounds
WO2005030746A1 (en) 2003-09-24 2005-04-07 Glaxo Group Limited Calcilytic compounds
JP2007523076A (ja) * 2004-02-06 2007-08-16 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
US20080300292A1 (en) 2004-11-08 2008-12-04 Nitromed, Inc Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders
WO2006078995A1 (en) 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use

Also Published As

Publication number Publication date
NZ540275A (en) 2007-11-30
NO20053071L (no) 2005-06-22
ES2388277T3 (es) 2012-10-11
US8399517B2 (en) 2013-03-19
AU2003291157A1 (en) 2004-06-18
OA12962A (en) 2006-10-13
CA2507226C (en) 2011-11-15
AP2113A (en) 2010-03-04
IL168704A (en) 2010-12-30
JP4489597B2 (ja) 2010-06-23
CN1741985A (zh) 2006-03-01
DK1569892T3 (da) 2012-08-27
HK1082914A1 (en) 2006-06-23
SI1569892T1 (sl) 2012-09-28
WO2004047751A2 (en) 2004-06-10
US20130158114A1 (en) 2013-06-20
IS2897B (is) 2014-09-15
MY143244A (en) 2011-04-15
CO5570664A2 (es) 2005-10-31
MXPA05005574A (es) 2005-07-27
EP1569892A2 (en) 2005-09-07
PT1569892E (pt) 2012-09-06
AU2003291157C1 (en) 2011-05-12
EP1569892B1 (en) 2012-06-13
PL211571B1 (pl) 2012-05-31
TW200510276A (en) 2005-03-16
US20090163589A1 (en) 2009-06-25
EP1569892A4 (en) 2010-09-15
EA200500878A1 (ru) 2005-10-27
EA009603B1 (ru) 2008-02-28
JP2006507348A (ja) 2006-03-02
US20150183723A1 (en) 2015-07-02
BR0316544A (pt) 2005-10-04
PL376965A1 (pl) 2006-01-09
AU2003291157B2 (en) 2011-01-20
AR042132A1 (es) 2005-06-08
NO332304B1 (no) 2012-08-20
US8586631B2 (en) 2013-11-19
US20140057980A1 (en) 2014-02-27
KR20050086786A (ko) 2005-08-30
US8980950B2 (en) 2015-03-17
IS7880A (is) 2005-06-02
US7514473B2 (en) 2009-04-07
CN1325466C (zh) 2007-07-11
US20110054021A1 (en) 2011-03-03
US7829594B2 (en) 2010-11-09
WO2004047751A3 (en) 2004-08-19
AP2005003320A0 (en) 2005-06-30
MA27528A1 (fr) 2005-09-01
US20060058391A1 (en) 2006-03-16
PE20040845A1 (es) 2004-11-28
ZA200504104B (en) 2006-03-29
UA81642C2 (ru) 2008-01-25
KR20110124806A (ko) 2011-11-17
KR101142697B1 (ko) 2012-05-10
TWI316511B (en) 2009-11-01
US9227914B2 (en) 2016-01-05
UY28089A1 (es) 2004-06-30
CA2507226A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
ATE461217T1 (de) Glp-1-verbindungen
CY2014001I1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
UY28348A1 (es) Compuestos novedosos
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20055450D0 (no) Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon
SE0301650D0 (sv) Novel compounds
NO20043107L (no) Bronnsementeringsbestanddeler for kalde omgivelser
DE602004032105D1 (de) Elektronenquelle
DE60220667D1 (de) Stromquelle
DE60326201D1 (de) Unpolarisierte Multiwellenlängenquelle
ATE425962T1 (de) Peptid-deformylase-hemmer
SE0302361D0 (sv) Inhibering av upptagning av monoamin
NO20005548L (no) Mykobakterieinhibitorer
DE60124148D1 (de) Kalzilytische verbindungen
ATE312077T1 (de) Peptiddeformylase-hemmer
ATE548037T1 (de) Peptid-deformylase-hemmer
NO20044186L (no) Peptid-deformylaseinhibitorer
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ATE531690T1 (de) Inhibitoren von peptiddeformylase
ATE309984T1 (de) Peptid-deformylase-hemmer
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα